-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Reviewing MusclePharm (OTCMKTS:MSLP) and Adamis Pharmaceuticals (NASDAQ:ADMP)
Reviewing MusclePharm (OTCMKTS:MSLP) and Adamis Pharmaceuticals (NASDAQ:ADMP)
MusclePharm (OTCMKTS:MSLP – Get Rating) and Adamis Pharmaceuticals (NASDAQ:ADMP – Get Rating) are both small-cap consumer staples companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, institutional ownership, analyst recommendations and profitability.
Insider & Institutional Ownership
15.5% of MusclePharm shares are owned by institutional investors. Comparatively, 8.6% of Adamis Pharmaceuticals shares are owned by institutional investors. 60.7% of MusclePharm shares are owned by insiders. Comparatively, 5.9% of Adamis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Get MusclePharm alerts:Earnings and Valuation
This table compares MusclePharm and Adamis Pharmaceuticals' revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
MusclePharm | $50.04 million | 0.07 | -$12.87 million | ($0.58) | -0.17 |
Adamis Pharmaceuticals | $2.21 million | 14.59 | -$45.83 million | N/A | N/A |
Profitability
This table compares MusclePharm and Adamis Pharmaceuticals' net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
MusclePharm | -38.51% | N/A | -169.56% |
Adamis Pharmaceuticals | N/A | -151.88% | -96.12% |
Analyst Ratings
This is a breakdown of current ratings and recommmendations for MusclePharm and Adamis Pharmaceuticals, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
MusclePharm | 0 | 0 | 0 | 0 | N/A |
Adamis Pharmaceuticals | 0 | 1 | 0 | 0 | 2.00 |
Volatility & Risk
MusclePharm has a beta of 0.17, suggesting that its share price is 83% less volatile than the S&P 500. Comparatively, Adamis Pharmaceuticals has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500.
Summary
MusclePharm beats Adamis Pharmaceuticals on 5 of the 9 factors compared between the two stocks.
About MusclePharm
(Get Rating)
MusclePharm Corporation develops, manufactures, markets, and distributes sports nutrition products and nutritional supplements in the United States and internationally. The company offers a range of performance powders, capsules, tablets, gels, and on-the-go ready to eat snacks. Its MusclePharm brand product portfolio includes combat protein powder and combat crunch protein bars; and essential supplements, such as a BCAA, creatine, glutamine, carnitine, CLA, fish oil, multi-vitamin, and other products. The company also provides FitMiss branded sports nutrition products, which are formulated primarily for the female body to support women in the areas of weight management, lean muscle mass, body composition, and general health and wellness; and functional energy beverages under the Combat Energy and FitMiss Energy brands. It sells its products to various athletes and fitness enthusiasts. The company was incorporated in 2006 and is based in Las Vegas, Nevada.
About Adamis Pharmaceuticals
(Get Rating)
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease in the United States. The company's product candidates comprise SYMJEPI epinephrine pre-filled syringe injectable products for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products for the treatment of asthma; and naloxone injection for the treatment of opioid overdose. It also offers APC400, a tempol gel use of reducing radiation dermatitis in patients undergoing treatment for cancer; and APC410 for the treatment of respiratory diseases, including asthma, respiratory syncytial virus, influenza, and COVID-19. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, and injectables; and veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation was founded in 2006 and is headquartered in San Diego, California.
Receive News & Ratings for MusclePharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MusclePharm and related companies with MarketBeat.com's FREE daily email newsletter.
MusclePharm (OTCMKTS:MSLP – Get Rating) and Adamis Pharmaceuticals (NASDAQ:ADMP – Get Rating) are both small-cap consumer staples companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, institutional ownership, analyst recommendations and profitability.
穆斯克爾帕姆(場外交易代碼:MSLP-GET評級)和阿達米斯製藥(納斯達克:ADMP-GET評級)都是小盤消費品公司,但哪隻股票更優?我們將根據兩家公司的估值、收益、風險、股息、機構所有權、分析師建議和盈利能力等方面的實力進行比較。
Insider & Institutional Ownership
內部人與機構所有權
15.5% of MusclePharm shares are owned by institutional investors. Comparatively, 8.6% of Adamis Pharmaceuticals shares are owned by institutional investors. 60.7% of MusclePharm shares are owned by insiders. Comparatively, 5.9% of Adamis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
該公司15.5%的股份由機構投資者持有。相比之下,機構投資者持有Adamis PharmPharmticals 8.6%的股份。MusclePharm 60.7%的股份由內部人士持有。相比之下,Adamis PharmPharmticals 5.9%的股份由內部人士持有。強大的機構持股表明,捐贈基金、大型基金管理公司和對衝基金相信,一隻股票有望實現長期增長。
Earnings and Valuation
收益和估值
This table compares MusclePharm and Adamis Pharmaceuticals' revenue, earnings per share and valuation.
該表格比較了MusclePharm和Adamis PharmPharmticals的營收、每股收益和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
MusclePharm | $50.04 million | 0.07 | -$12.87 million | ($0.58) | -0.17 |
Adamis Pharmaceuticals | $2.21 million | 14.59 | -$45.83 million | N/A | N/A |
總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
穆斯克爾帕姆 | 5,004萬美元 | 0.07 | -1287萬美元 | ($0.58) | -0.17 |
Adamis製藥公司 | 221萬美元 | 14.59 | -4,583萬美元 | 不適用 | 不適用 |
Profitability
盈利能力
This table compares MusclePharm and Adamis Pharmaceuticals' net margins, return on equity and return on assets.
此表比較了MusclePharm和Adamis製藥公司的淨利潤率、股本回報率和資產回報率。
Net Margins | Return on Equity | Return on Assets | |
MusclePharm | -38.51% | N/A | -169.56% |
Adamis Pharmaceuticals | N/A | -151.88% | -96.12% |
淨利潤率 | 股本回報率 | 資產回報率 | |
穆斯克爾帕姆 | -38.51% | 不適用 | -169.56% |
Adamis製藥公司 | 不適用 | -151.88% | -96.12% |
Analyst Ratings
分析師評級
This is a breakdown of current ratings and recommmendations for MusclePharm and Adamis Pharmaceuticals, as provided by MarketBeat.com.
這是由MarketBeat.com提供的MusclePharm和Adamis PharmPharmticals的當前評級和推薦細目。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
MusclePharm | 0 | 0 | 0 | 0 | N/A |
Adamis Pharmaceuticals | 0 | 1 | 0 | 0 | 2.00 |
銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
穆斯克爾帕姆 | 0 | 0 | 0 | 0 | 不適用 |
Adamis製藥公司 | 0 | 1 | 0 | 0 | 2.00 |
Volatility & Risk
波動性與風險
MusclePharm has a beta of 0.17, suggesting that its share price is 83% less volatile than the S&P 500. Comparatively, Adamis Pharmaceuticals has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500.
MusclePharm的貝塔係數為0.17,這表明其股價的波動性比標準普爾500指數低83%。相比之下,Adamis PharmPharmticals的貝塔係數為1.05,這表明其股價的波動性比標準普爾500指數高出5%。
Summary
摘要
MusclePharm beats Adamis Pharmaceuticals on 5 of the 9 factors compared between the two stocks.
在比較兩隻股票的9個因素中,MusclePharm在5個方面擊敗了Adamis PharmPharmticals。
About MusclePharm
關於MusclePharm
(Get Rating)
(獲取評級)
MusclePharm Corporation develops, manufactures, markets, and distributes sports nutrition products and nutritional supplements in the United States and internationally. The company offers a range of performance powders, capsules, tablets, gels, and on-the-go ready to eat snacks. Its MusclePharm brand product portfolio includes combat protein powder and combat crunch protein bars; and essential supplements, such as a BCAA, creatine, glutamine, carnitine, CLA, fish oil, multi-vitamin, and other products. The company also provides FitMiss branded sports nutrition products, which are formulated primarily for the female body to support women in the areas of weight management, lean muscle mass, body composition, and general health and wellness; and functional energy beverages under the Combat Energy and FitMiss Energy brands. It sells its products to various athletes and fitness enthusiasts. The company was incorporated in 2006 and is based in Las Vegas, Nevada.
公司在美國和國際上開發、製造、營銷和分銷運動營養品和營養補充劑。該公司提供一系列高性能粉末、膠囊、片劑、凝膠和隨時可用的零食。該公司的MusclePharm品牌產品組合包括戰鬥蛋白粉和戰鬥擠壓蛋白棒;以及支鏈氨基酸、肌酸、谷氨醯胺、肉鹼、共軛亞油酸、魚油、多種維生素和其他產品等基本補充劑。該公司還提供FitMisse品牌的運動營養產品,這些產品主要是為女性身體制定的,以支持女性在體重管理、瘦肌肉質量、身體成分以及一般健康和健康方面的需求;以及FitMisse Energy和FitMisse Energy品牌的功能能量飲料。它向各種運動員和健身愛好者銷售其產品。該公司成立於2006年,總部設在內華達州拉斯維加斯。
About Adamis Pharmaceuticals
關於Adamis製藥公司
(Get Rating)
(獲取評級)
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease in the United States. The company's product candidates comprise SYMJEPI epinephrine pre-filled syringe injectable products for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products for the treatment of asthma; and naloxone injection for the treatment of opioid overdose. It also offers APC400, a tempol gel use of reducing radiation dermatitis in patients undergoing treatment for cancer; and APC410 for the treatment of respiratory diseases, including asthma, respiratory syncytial virus, influenza, and COVID-19. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, and injectables; and veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation was founded in 2006 and is headquartered in San Diego, California.
Adamis製藥公司是一家專業生物製藥公司,在美國開發和銷售過敏、阿片類藥物過量、呼吸道和炎症性疾病治療領域的產品。該公司的候選產品包括SYMJEPI腎上腺素預填充注射器注射產品,用於緊急治療急性過敏反應,包括過敏反應;用於治療哮喘的乾粉吸入器產品;以及用於治療阿片類藥物過量的納洛酮注射劑。它還提供APC400,這是一種用於減少正在接受癌症治療的患者的放射性皮炎的坦普爾凝膠;以及APC410,用於治療呼吸道疾病,包括哮喘、呼吸道合胞病毒、流感和新冠肺炎。此外,該公司還提供皮質類固醇、激素替代療法、醫院外包產品和注射劑;以及動物獸藥產品。Adamis製藥公司成立於2006年,總部設在加利福尼亞州聖地亞哥。
Receive News & Ratings for MusclePharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MusclePharm and related companies with MarketBeat.com's FREE daily email newsletter.
接受MusclePharm日報的新聞和評級-在下面輸入您的電子郵件地址,即可通過MarketBeat.com的免費每日電子郵件時事通訊收到對MusclePharm和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧